https://www.marketscreener.com/quote/stock/CELGENE-8736/news/Celgene-Results-from-Phase-IIIb-Study-of-POMALYST-IMNOVID-pomalidomide-Plus-Low-Dose-dexamet-19551890/?utm_source=telegram&utm_medium=social&utm_campaign=share